Merck KGaA says FDA grants breakthrough designation to lupus drug enpatoran

  • Merck KGaA unit EMD Serono received FDA Breakthrough Therapy designation for enpatoran to treat lupus with active cutaneous manifestations.
  • Designation follows Phase 2 WILLOW data showing clinically meaningful symptom improvement, strongest in patients with active skin disease.
  • Company has launched ELOWEN 1 and ELOWEN 2 global Phase 3 trials to support potential approval across cutaneous and systemic lupus symptoms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202607080800BIZWIRE_USPR_____20260706_BW743878) on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.